Advertisement

Topics

Crescendo Biologics Ltd Company Profile

14:38 EST 14th December 2018 | BioPortfolio

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.


News Articles [502 Associated News Articles listed on BioPortfolio]

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Comp...

Takeda Licenses Oncology Target from Crescendo Biologics

Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.

Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration ...

Crescendo BiologicsDr Peter PackCEOTel:44 (0)1223 497140info@crescendobiologics.comorInstinctif PartnersMelanie Toyne-Sewell / Dr Christelle Kerouedan / Deborah BellTel:44 (0)20 7...

Takeda licenses Crescendo’s Humabodies

Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.

Crescendo hires ex-Roche R&D guru to develop T-cell technology

Backed with $70 million from a fundraising round earlier this year, UK biotech Crescendo Biologics has appointed a world-leading immuno-oncologist to its team. Dr Pavel Pisa is the UK-based company...

Crescendo grants Takeda rights to Humabody products

Crescendo Biologics granted Japan-based Takeda Pharmaceutical license to the former's Humabody products directed to an oncolo -More- 

Crescendo Biologics appoints Dr Richard Williams

Crescendo Biologics appoints non-executive director

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [98 Associated PubMed Articles listed on BioPortfolio]

Considerations for implementing an informatics system to support biologics drug discovery.

A comprehensive, well-functioning and scientifically aware informatics environment is of the utmost importance in supporting effective drug discovery programs. However, implementing such a system can,...

Advanced formulations for Intranasal Delivery of Biologics.

The global biologics market has been ever increasing over the last decades and is predicted to top Euro 350 by 2020. Facing this scenario, the parenteral route of biologics administration as hitherto ...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

Dose Increase beyond Labelled Dose of Biologics Is Associated With Incremental Pharmacy Costs: Results from a Real-World Study In the UK.

Evidence regarding dosing patterns of biologics among moderate to severe psoriasis patients and impact on costs in the United Kingdom (UK) is limited.

Clinical Trials [85 Associated Clinical Trials listed on BioPortfolio]

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to compare the efficacy of Biologics + Methotrexate with Biologics + Tacrolimus measured by the disease activity score 28 (DAS28) erythrocyte sedimentation rat...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Companies [277 Associated Companies listed on BioPortfolio]

Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the p...

Crescendo Pharmaceuticals

Crescendo was formed by ALZA for the purpose of selecting and developing human pharmaceutical products (the "Crescendo Products") and commercializing such products, most likely through licensing to AL...

Crescendo Bioscience, Inc.

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience develops quantitative, objective, biol...

Crescendo Bioscience

Crescendo Bioscience is a molecular diagnostics company focused in rheumatology and located in South San Francisco, CA. Crescendo Bioscience is developing quantitative, objective,...

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

More Information about "Crescendo Biologics Ltd" on BioPortfolio

We have published hundreds of Crescendo Biologics Ltd news stories on BioPortfolio along with dozens of Crescendo Biologics Ltd Clinical Trials and PubMed Articles about Crescendo Biologics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Crescendo Biologics Ltd Companies in our database. You can also find out about relevant Crescendo Biologics Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record